Mazor Robotics announces brain biopsy success

Company’s robotic navigation system carries out 3 biopsies.

June 12, 2012 07:01
1 minute read.

Brain 390. (photo credit: Nutritional Neuroscience)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Mazor Robotics Ltd. announced Monday that three procedures for obtaining brain tissue biopsies were successfully carried out in Germany using the company’s robotic system.

The procedures were carried out on live patients, in contrast to the previous clinical trials on cadavers. The three procedures were carried by two different neurosurgeons at HSK Hospital in Weisbaden.

Be the first to know - Join our Facebook page.

In the expert opinion of the surgeons, the procedures were a complete success.

Mazor said that the biopsies demonstrated the precision, stability, ease of use and high safety profile of the robotic system.

Mazor is expanding the applications of its robotic navigation system to brain surgery from its original use in spinal procedures. The company is planning the commercial launch of the system for neurosurgery in early 2013, after additional biopsies are carried out on live patients to optimize the system’s capabilities for the market’s needs and after regulatory approval is obtained.

Immediately after the commercial launch of the robotic system for the new applications, Mazor will demonstrate its proprietary navigation technology to specialists at the hospitals where the company works as the standard treatment for applications which use electrodes and implants for deep-brain- stimulation therapy.

Mazor said that both the US Food and Drug Administration (FDA) and EU CE Mark are reviewing the company’s robotic navigation surgical system for brain procedures, and that it expects to receive responses from them during the second half of 2012.


Mazor believes that the neurosurgery field is an important business opportunity, with 25,000 brain-tissue biopsies are carried out annually in the US alone.

The market for inserting and navigating implants for deep-brain-stimulation therapy is currently estimated at hundreds of millions of dollars.

Mazor CEO Ori Hadomi said, “We are very proud about the first successful robotically-guided procedures on the brain carried out in the world.

This is the first and major step for the company and a technological breakthrough.

The first brain procedures carried out in Germany bring Mazor much closer to the product’s commercial launch for brain procedures in early 2013.”

Mazor Robotic’s share price rose 7.3 percent by midday to NIS 3.92, giving a market cap of NIS 86 million.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection